Abstract
BackgroundAnti-TNFα agents and Rituximab fall within the FDA category B concerning fetal risk. However numerous case series and registry data of pregnancies exposed to these therapies are available in the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
